ABCL (AbCellera) Forward P/E Multiple
AbCellera Biologics (ABCL) leverages its team of top biologists to ensure technological leadership, as evidenced by the company's forward P/E ratio: the value 0.00 captures the current metric level. An expanding client base of biotech corporations is broadening market reach, while extensive diversification of partnerships with pharma behemoths via its AI platform minimizes the risk of losses from failed clinical trials.
Analytical breakdowns for AbCellera Biologics
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- debt and liquidity details:
- company profitability and valuation multiples indicators:
ABCL - Company Net Income|Projected Future Earnings AbCellera Biologics|ABCL - Price to Earnings Ratio|Forward P/E Multiple AbCellera Biologics Inc.|ABCL - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AbCellera Bio|ABCL - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months AbCellera|ABCL - Earnings per share for the last twelve months|Quarterly EPS earnings growth abcellera.com|ABCL - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year AbCellera Biologics
- total revenue and sales volume data:
Summary company analytics:AbCellera
The scale of the AbCellera Biologics (ABCL) AI ecosystem drives long-term market expectations, as reflected in the issuer's forward P/E dynamics. This indicator compares current market capitalization with projected earnings for future periods. The calculation is based on the ratio of the share price to expected earnings per share. For a biotech company, this serves as a measure of investors' willingness to pay a premium for platform exclusivity and high partner switching costs. Analyzing the trajectory of this metric allows for an assessment of the real margin of safety for the investment.
Competitors of AbCellera Biologics (ABCL)
Projected Price to Earnings ARGX (Argenx)|BNTX (BioNTech Group) - Future Price to Earnings Multiple|Forward P/E Multiple ABVX (Abivax SA)|Market Cap to Projected Earnings admabiologics.com (ADMA)|PTGX - Future Price to Earnings|Immunovant Inc (IMVT) - Projected Price to Earnings|Kiniksa Corp (KNSA) - Future Price to Earnings|Projected Price to Earnings Grifols, S.A.|Projected Price to Earnings ADPT|Forward P/E Multiple celldex.com|Future Price to Earnings Aurinia Pharma (AUPH)|BioCryst Pharmaceuticals - Price to Future Earnings Ratio|Forward P/E Multiple VERA (veratx.com)|Dianthus Pharma (DNTH) - Projected Price to Earnings Ratio|PHVS - Future Price to Earnings|tourmalinebio.com - Market Cap to Future Earnings Ratio|Precigen (PGEN) - Future Price to Earnings|Pharming Group - Future Price to Earnings Multiple|Future Price to Earnings Nektar Therapeutics Inc|UPB (Upstream Pharma) - Market Cap to Future Earnings Ratio|Forward P/E Multiple ZBIO|Forward P/E Multiple immunome.com (IMNM)|Forward P/E Multiple GOSS (gossamerbio.com)|Market Cap to Projected Earnings KalVista Pharma (KALV)|SEPN - Future Price to Earnings|Market Cap to Projected Earnings Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Projected Price to Earnings|Price to Expected Earnings Ratio RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - Forward P/E Multiple|ATXS (Astria Therapeutics, Inc.) - Market Cap to Future Earnings Ratio|Future Price to Earnings engene.com (ENGN)|RAPT (RAPT Therapeutics, Inc.) - Future Price to Earnings Multiple|Aerovate Therapeutics - Projected Price to Earnings|Future Price to Earnings Multiple ACRS|Kyverna Therapeutics, Inc - Forward P/E Multiple|Price to Expected Earnings Ratio TLSA|CABA: Forward P/E Multiple|Projected Price to Earnings Ventyx Bio|Future Price to Earnings Theratechnologies, Inc.|Projected Price to Earnings Ratio Avalo Therapeutics AVTX|Forward P/E Multiple ELDN|AGEN (Agenus, Inc.) - Future Price to Earnings Multiple|Future Price to Earnings Climb Bio, Inc. CLYM|Zura Bio Limited (ZURA) - Projected Price to Earnings Ratio|ATYR: Projected Price to Earnings|adagene.com (ADAG) - Projected Price to Earnings|Ikena Oncology (IMA) - Future Price to Earnings|Projected Price to Earnings Shattuck Labs, Inc.|Future Price to Earnings equilliumbio.com|Projected Price to Earnings connectbiopharm.com (CNTB)|Forward P/E Multiple IMUX|Market Cap to Projected Earnings Atara Bio|Future Price to Earnings InflaRx N.V. IFRX|X4 Pharmaceuticals - Future Price to Earnings|ACET: Projected Price to Earnings|Future Price to Earnings Multiple CELU (celularity.com)|INMB: Forward P/E Multiple|BRNS: Market Cap to Future Earnings Ratio|KZR (Kezar Life Sciences, Inc.) - Forward P/E Multiple|SAB Biotherapeutics Inc. (SABS) - Market Cap to Projected Earnings|Forward P/E Multiple AKTX|Future Price to Earnings ENLV (Enlivex Therapeutics Ltd)|Future Price to Earnings Q32 Bio Inc. QTTB|GOVX - Projected Price to Earnings|EDSA - Future Price to Earnings|Projected Price to Earnings Ratio iBio|CARM: Forward P/E Multiple|Price to Expected Earnings Ratio XTLB (XTL Biopharmaceuticals, Ltd.)|Future Price to Earnings boltbio.com|Forward P/E Multiple HCW Biologics|Forward P/E Multiple APVO|AIM - Projected Price to Earnings Ratio|Forward P/E Multiple ADTX (Aditxt Inc.)|Market Cap to Projected Earnings GRI Bio, Inc. (GRI)|XRTX - Future Price to Earnings|reshapelifesciences.com (HIND) - Projected Price to Earnings|REVB: Forward P/E Multiple|Indaptus Therapeutics, Inc. - Future Price to Earnings Multiple|Future Price to Earnings Scinai|Projected Price to Earnings Ratio CalciMedica, Inc. CALI|Future Price to Earnings Affimed NV (AFMD)|Forward P/E Multiple Allakos Inc (ALLK)|Future Price to Earnings hookipapharma.com HOOK|Forward P/E Multiple IGM Biosciences, Inc. IGMS|iTeos Pharma - Forward P/E Multiple|OCEA - Forward P/E Multiple|TCBP: Forward P/E Multiple|Third Harmonic Bio - Future Price to Earnings Multiple
